Flow cytometry studies have reported an association between lower regulatory T cells (Treg) in cord blood and subsequent food allergy. Flow cytometry, however, is a resource-intensive technique. We therefore aimed to develop an epigenetic biomarker (nTreg) that correlates with the proportion of naïve regulatory T cells (nTreg) in cord blood white cells (CBWCs) measured by flow cytometry. We then investigated the association between nTreg and subsequent food allergy.

Inconsistent documentation of known allergies in electronic patient records (EPRs) poses a major patient safety risk. Unlike drug allergies, food and non-drug allergens lack standardised documentation frameworks. This study evaluated how such allergies are recorded across NHS Trusts and the extent of avoidable harm from exposures.

Non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is characterised by the clinical triad of hypersensitivity to NSAIDs, nasal polyposis, and asthma. The cells and mediators causing acute symptoms when driving the hypersensitivity reaction to acetylsalicylic acid (ASA) ingestion, remain poorly defined.

Demand for paediatric allergy services has risen significantly over the past 20 years. National health datasets suggest almost 40% of children have an allergy diagnosis. Existing service standards from the Royal College of Paediatrics and Child Health (RCPCH) have focused on specific disease care pathways and the interface between primary and secondary care services. Given strategic changes to NHS children and young people's services, we undertook a collaborative project between RCPCH and the British Society of Allergy and Clinical Immunology (BSACI) to define service priorities for Paediatric Allergy Care accreditation in the UK.

Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia. Clinical trials show high rates of allergic desensitisation and remission are being achieved, particularly in young children, but significant variability in protocols and implementation prevents large-scale evaluation of clinical and patient-reported safety, effectiveness and long-term outcomes. A standardised national model of care OIT program has not been previously attempted. In Australia, the National Allergy Centre of Excellence partnered with 10 paediatric hospitals to develop and implement the ADAPT OIT Program, which aims to change the trajectory from 'Allergy Development to an Accelerated Pathway to Tolerance'. The Program was designed after extensive international expert and consumer consultation, and attempts to be pragmatic, feasible by using existing resources, and equitable, with out-of-pocket costs to families limited to the purchase of the OIT product, store-bought peanut flour.

The recommended first-line treatment for anaphylaxis in the community is intramuscular injection of adrenaline. The treatment is a standardised dose of either a 150 μg or a 300 μg adrenaline auto-injector (AAI) device depending upon the patient's weight. Currently, no standardised mechanisms exist to transition patients onto the higher 300 μg dose when they reach 25-30 kg (depending upon the manufacturer).